ATOS Stock Chart & Stats
$41.50
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$31.00 - $322.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)95.00
Market Cap
$400.26M
Enterprise Value$13.53
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Aug 17, 2026EPS Estimate
-17.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding9,974,998
10 Day Avg. Volume7
30 Day Avg. Volume95
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$278.12Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ATOS FAQ
What was Atossa Therapeutics, Inc.’s price range in the past 12 months?
Atossa Therapeutics, Inc. lowest stock price was $31.00 and its highest was $322.50 in the past 12 months.
What is Atossa Therapeutics, Inc.’s market cap?
Atossa Therapeutics, Inc.’s market cap is $400.26M.
When is Atossa Therapeutics, Inc.’s upcoming earnings report date?
Atossa Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 23 days.
How were Atossa Therapeutics, Inc.’s earnings last quarter?
Atossa Therapeutics, Inc. released its earnings results on May 08, 2026. The company reported -$19.435 earnings per share for the quarter, missing the consensus estimate of -$17.334 by -$2.101.
Is Atossa Therapeutics, Inc. overvalued?
According to Wall Street analysts Atossa Therapeutics, Inc.’s price is currently Undervalued.
Does Atossa Therapeutics, Inc. pay dividends?
Atossa Therapeutics, Inc. does not currently pay dividends.
What is Atossa Therapeutics, Inc.’s EPS estimate?
Atossa Therapeutics, Inc.’s EPS estimate is -17.95.
How many shares outstanding does Atossa Therapeutics, Inc. have?
Atossa Therapeutics, Inc. has 9,974,998 shares outstanding.
What happened to Atossa Therapeutics, Inc.’s price movement after its last earnings report?
Atossa Therapeutics, Inc. reported an EPS of -$19.435 in its last earnings report, missing expectations of -$17.334. Following the earnings report the stock price went down -3%.
Which hedge fund is a major shareholder of Atossa Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MX:ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$278.12